Karine Sargsyan, formerly director of one of the world’s largest clinical biobanks, was named scientific director of Cedars-Sinai Cancer’s OncoBiobank.
The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recognized with official accreditation for CAR T-cell therapy from the Foundation for the Accreditation of Cellular Therapy, an international accrediting body. The program was also ranked among the top adult bone marrow transplant programs in the U.S. for a third year.
Jeannie Shen was appointed medical director of the Breast Program at Huntington Hospital, an affiliate of Cedars-Sinai, and medical director of the International Health Program at Cedars-Sinai Cancer at Huntington Hospital.
Yuan Yuan, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, was named director of Breast Oncology at Cedars-Sinai Cancer.
Cedars-Sinai Cancer has launched a Clinical and Regulatory Sciences Graduate Certificate Program, which begins in the fall of 2022.
Ju Dong Yang was named medical director of the Liver Cancer Program at Cedars-Sinai Cancer Center.
Researchers at Cedars-Sinai Cancer and Johns Hopkins University discovered a novel three-step treatment that disrupts the pancreatic tumor microenvironment in laboratory mice.
Alicia M. Terando was named the San Gabriel Valley regional medical director for surgical oncology at Cedars-Sinai Cancer at the Huntington Cancer Center.
Researchers from Cedars-Sinai Cancer analyzed patient samples and studies conducted in animal models to identify a novel role for the IL-27 signaling pathway in hepatocellular carcinoma.
Racial and ethnic minorities diagnosed with advanced liver cancer have a lower chance of receiving immunotherapy, the most effective treatment for patients with the disease, according to a study led by Cedars-Sinai Cancer investigators.
